In a challenging market environment, TPST, also known as Ovascience Inc, has seen its stock price touch a 52-week low, reaching a concerning $0.92. This significant downturn reflects a broader trend ...

Tempest Therapeutics TPST stock skyrocketed 2879% after it announced positive new data from its global phase Ib/II first-line liver cancer study, evaluating TPST-1120, in combination with the standard ...

Tempest Therapeutics, Inc. TPST announced that it is planning to explore strategic options to advance the clinical studies on its pipeline candidates aimed at increasing stockholder value. The ...

TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpected RECIST responses observed with TPST-1120 combined ...

The average one-year price target for Tempest Therapeutics (NASDAQ:TPST) has been revised to 22.10 / share. This is an increase of 38.30% from the prior estimate of 15.98 dated October 4, 2023. The ...

Tempest Therapeutics (NASDAQ:TPST) said its drug TPST-1120 showed clinically-meaningful improvement in multiple categories in patients with a type of liver cancer as per early data from a phase 1b/2 ...

Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ:TPST). This little-known clinical-stage oncology company has gone from trading at 30 cents per share 24 hours ago to its current ...